Braveheart Bio (BRVE) vs Structure Therapeutics (GPCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Structure Therapeutics is the larger company by market cap ($1.83 billion vs $1.79 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | GPCR |
|---|---|---|
| Share price | $19.88 | $25.64 |
| Market cap | $1.79B | $1.83B |
| 1-day change | +4.11% | -0.12% |
| YTD return | — | -63.09% |
| 1-year return | — | -9.77% |
| EPS (TTM) | $-6.08 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-141.20M |
| 52-week high | $32.00 | $94.90 |
| 52-week low | $17.86 | $25.09 |
| Distance from 52-week high | -37.89% | -72.98% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +127.67% | +312.56% |
| Average volume | 558.38K | 965.00K |
| Shares outstanding | 90.04M | 71.31M |
| Employees | 49 | 281 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
BRVE vs GPCR FAQ
Which is bigger, Braveheart Bio or Structure Therapeutics?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.83B compared with $1.79B for Braveheart Bio (BRVE).
Are Braveheart Bio and Structure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.